

# A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

NCT07408219

---

Status	RECRUITING
Sponsor	Novartis Pharmaceuticals
Enrollment	350 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Healthcare provider (HCP) participants eligible to refer patients for inclusion in this study must meet all the following criteria:
- Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible.
- Manage CSU patients within their practice.
- Enrolled in the research network or are referred HCPs who agree to participate.

### Exclusion (13)

- Patients eligible for inclusion in this study must meet all of the following criteria:
- e 18years of age.
- Diagnosed with CSU by an HCP.
- Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment.
- Have access to an electronic device with internet capabilities.
- ... and 8 more (see full listing online)

## Locations (1 total)

---

Novartis, East Hanover, New Jersey, United States